Tirzepatide and exercise training in obesity

被引:1
|
作者
Bagherzadeh-Rahmani, Behnam [1 ]
Marzetti, Emanuele [2 ,3 ]
Karami, Esmail [4 ]
Campbell, Bill I. [5 ]
Fakourian, Ali [6 ]
Haghighi, Amir Hossein [2 ]
Mousavi, Seyyed Hossein [7 ]
Heinrich, Katie M. [8 ]
Brazzi, Luca [9 ]
Jung, Friedrich [10 ]
Baker, Julien S. [11 ]
Patel, Darpan I. [12 ]
机构
[1] Hakim Sabzevari Univ, Fac Sport Sci, Dept Exercise Physiol, Sabzevar, Iran
[2] Univ Cattolica Sacro Cuore, Dept Geriatr & Orthoped, Rome, Italy
[3] Fdn Policlin Univ A Gemelli IRCCS, Rome, Italy
[4] AJA Univ Med Sci, Fac Med, Dept Physiol, Tehran, Iran
[5] Univ S Florida, Performance & Phys Enhancement Lab, Tampa, FL USA
[6] Islamic Azad Univ, Dept Exercise Physiol, Cent Tehran Branch, Tehran, Iran
[7] AJA Univ Med Sci, Sch Med, Dept Cardiol, Tehran, Iran
[8] Kansas State Univ, Dept Kinesiol, Manhattan, KS USA
[9] Univ Turin, Dept Surg Sci, Turin, Italy
[10] Brandenburg Univ Technol Cottbus Senftenberg, Inst Biotechnol, Mol Cell Biol, Senftenberg, Germany
[11] Hong Kong Baptist Univ, Dept Sport Phys Educ & Hlth, Kowloon, Hong Kong, Peoples R China
[12] Univ Texas Med Branch, Sch Nursing, Galveston, TX USA
关键词
Obesity; combined training; GIP; GLP-1; Tirzepatide; GLP-1 RECEPTOR AGONIST; INSULIN-RESISTANCE; PHYSICAL-ACTIVITY; DUAL GIP; INCRETINS; EFFICACY; FITNESS; MUSCLE;
D O I
10.3233/CH-242134
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVES: The purpose of this study was to investigate the effects of 6 weeks of resistance training (RT) combined with aerobic training (AT) and Tirzepatide supplementation on lipid profiles, insulin resistance, anthropometric characteristics and physical fitness in prediabetic obese soldiers. METHODS: 61 obese men were randomly divided into six groups: Placebo; Tirzepatide 5 mg (T5); Tirzepatide 2.5 mg (T2.5); Hypertrophy, Strength, Power-Circuit Training + Placebo (Ex + P); Hypertrophy, Strength, Power-Circuit Training + Tirzepatide 5 mg (Ex + T5); Hypertrophy, Strength, Power-Circuit Training + Tirzepatide 2.5 mg (Ex + T2.5). All training groups performed aerobic training (AT) after resistance training. Subjects trained for six weeks, three sessions per week. Before and after the intervention period, the participants were evaluated for anthropometric measures, body composition [body weight, body mass index (BMI), waist circumference (WC), waist to hip ratio (WHR) and fat mass (FM)], cardiorespiratory fitness (VO2max), 2 max), and muscle strength (chest press 1RM and leg press 1RM). Blood biochemistry evaluations included triglyceride (TG), total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), fasting blood glucose (FBG), insulin level and insulin resistance (HOMA-IR). To evaluate the differences between the groups, ANCOVA statistical method was used along with Bonferroni's post hoc test, and the significance level was P < 0.05. RESULTS: Body weight, BMI, WC, FM, FBG, LDL-C, TC, TG and HOMA-IR were significantly decreased in Ex+P, + P, Ex + T5 and Ex + T2.5 groups compared to Placebo, T5 and T2.5 groups. WHR significantly decreased in Ex + P, Ex + T5 and Ex+T2.5 + T2.5 groups compared to Placebo group. HDL-C, chest press and leg press significantly increased in Ex+P, + P, Ex + T5 and Ex + T2.5 groups compared to Placebo, T5 and T2.5 groups. VO2max 2 max significantly increased and insulin significantly decreased in Ex+P + P group compared to Placebo, T5 and T2.5 groups. FM, FBG and TG were significantly decreased in both the T2.5 and T5 groups compared to Placebo group. HOMA-IR, LDL-C and TC significantly decreased in the T5 group compared to Placebo group. Also, leg press significantly increased in Ex+P + P group compared to all other groups. CONCLUSIONS: Performing six weeks of combined resistance and aerobic training in the form of RT + AT alone is more effective than the simultaneous use of Tirzepatide on cardiorespiratory fitness, strength, and modulating insulin levels. Taking Tirzepatide in doses of 5 mg and 2.5 mg in combination with exercise training did not have a significant advantage over exercise training alone. Finally, taking Tirzepatide in doses of 5 mg or 2.5 mg in combination with exercise training is not significantly superior to each other.
引用
收藏
页码:465 / 480
页数:16
相关论文
共 50 条
  • [21] Tirzepatide - A major breakthrough in the fight against obesity
    Habiba, Ume
    Iqbal, Amna
    Kumar, Satesh
    JOURNAL OF THE PAKISTAN MEDICAL ASSOCIATION, 2023, 73 (03) : 741 - 741
  • [22] Tirzepatide Once Weekly for the Treatment of Obesity Reply
    Jastreboff, Ania M.
    Aronne, Louis J.
    Stefanski, Adam
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (15): : 1434 - 1435
  • [23] Tirzepatide and potential use for metabolically healthy obesity
    Copur, Sidar
    Tanriover, Cem
    Yavuz, Furkan
    Tuttle, Katherine R.
    Kanbay, Mehmet
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2023, 113 : 1 - 5
  • [24] Tirzepatide (Mounjaro)- a novel Pharmacotherapeutic Agent for Obesity
    Tayyaba
    Siddiqui, Tasmiyah
    Doultani, Payal Rani
    JOURNAL OF THE PAKISTAN MEDICAL ASSOCIATION, 2023, 73 (05) : 1171 - 1171
  • [25] Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity
    Malhotra, Atul
    Grunstein, Ronald R.
    Fietze, Ingo
    Weaver, Terri E.
    Redline, Susan
    Azarbarzin, Ali
    Sands, Scott A.
    Schwab, Richard J.
    Dunn, Julia P.
    Chakladar, Sujatro
    Bunck, Mathijs C.
    Bednarik, Josef
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 33 (04):
  • [26] Tirzepatide for Weight Reduction in Chinese Adults With Obesity
    Chen, Zhao
    Li, Wenqiang
    Deng, Zhiping
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2024, 332 (24):
  • [27] Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity
    Xiao, Yifan
    Meng, Jiahao
    Gao, Shuguang
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2024, 331 (19): : 1673 - 1676
  • [28] Tirzepatide Lowered Blood Pressure in People With Obesity
    Harris, Emily
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2024, 331 (10): : 821
  • [29] Tirzepatide to treat obesity: phase III results
    Ray, Katrina
    NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2022, 19 (08) : 488 - 488
  • [30] Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity
    Malhotra, Atul
    Grunstein, Ronald R.
    Fietze, Ingo
    Weaver, Terri E.
    Redline, Susan
    Azarbarzin, Ali
    Sands, Scott A.
    Schwab, Richard J.
    Dunn, Julia P.
    Chakladar, Sujatro
    Bunck, Mathijs C.
    Bednarik, Josef
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 391 (13): : 1193 - 1205